Slide 1: CellaVision Annual General Meeting 2012
CellaVision Annual General Meeting 2012 1 5/2/2012
Slide 2: Digital solutions for analysis of blood and other body fluids
Digital solutions for analysis of blood and other body fluids • Efficiency cost reduction, increased productivity and shorter response times • Proficiency increased quality of results • Connectivity between sites; enhanced opportunity for collaboration and sharing of competences 2 5/2/2012
Slide 3: Market
Market • CellaVision is world leader in a market with large potential, offering automated digital cell morphology • The hematology analysis market comprises more than 1 billion CBC tests a year – manual differential work equivalent to more than USD 1 billion • CellaVision’s market includes products
Slide 4: CellaVision in short
CellaVision in short • Headquarters in Lund, Sweden. • 64 employees. • Sales through distributors. Direct sales through subsidiaries in the Nordic countries, the US, Canada and Japan. • Manufacturing outsourced to Kitron AB, Sweden. • Competition: manual microscopy and competing products in early ph
Slide 5: Global customer base
Global customer base >1000 systems mainly in Europe and North America • Global distribution through Sysmex and Beckman Coulter • Direct sales in the US, Canada, Japan and the Nordic countries • Hospital and commercial hematology laboratories • The hospital demand for efficiency and cost reduction ma
Slide 6: CASE: Karolinska University Hospital, Stockholm
CASE: Karolinska University Hospital, Stockholm Faster, safer, and more standardized results Stockholm’s county council’s successful investment in hematology was awarded the Golden Apple. Six laboratories are linked together. Huddinge Danderyd Solna Södertälje Norrtälje Söder, Stockholm
Slide 7: Financial performance 2007–2011
Financial performance 2007–2011 1,000 systems sold, increased sales for the tenth year in succession, and profit for the fifth year in succession Sales, EBIT MSEK Personell 7
Slide 8: 2011: Major growth in North America and improved delivery capacity with strengthened cash flow
2011: Major growth in North America and improved delivery capacity with strengthened cash flow Q4 Q4 Full year Full year MSEK 2011 2010 2011 2010 Net sales +11% 46.4 41.9 + 18% 155.4 131.6 Gross profit 32.2 28.9 101.4 87.6 Operating profit 6.9 9.1 17.8 13.9 Operating margin % 15.0 21.7 11.5 10.6 Pro
Slide 9: Sales per geographical region, full year
Sales per geographical region, full year 2011 2010 Rest of the World Rest of the World Europe Europe North America North America 9
Slide 10: Continued growth through global expansion and partnerships
Continued growth through global expansion and partnerships • Major growth in North America. The distribution strategy with parallel, global sales channels in the US makes a considerable contribution to the positive sales trend. • In Europe, acceptance of CellaVision’s digital technology is particula
Slide 11: Improved production and supply potential
Improved production and supply potential • Stable production and delivery rates adapted to higher sales targets. Positive impact on our cash flow, particularly in the fourth quarter. • Key components for the CellaVision DM1200 analyzer were secured, for example through design changes and own purchas
Slide 12: Q1 2012: Stronger quarter than expected
Q1 2012: Stronger quarter than expected More than 30 per cent growth and doubled profit Q1 Q1 Full year MSEK 2012 2011 2011 Net sales +32% 40.4 30.6 + 18% 155.4 Gross profit 27.1 20.8 101.4 Operating profit 5.4 2.5 17.8 Operating margin % 13.4 8.2 11.5 Profit before tax 4.4 0.3 18.5 Cash flow ‐0.3 4
Slide 13: Financial performance
Financial performance 12 months rolling and per quarter Q408–Q112, MSEK 13 5/2/2012
Slide 14: Sales per geographical region
Sales per geographical region Q1 2012 (2011) Asia Pacific 5% (13) North America 58% (48) Europe 37% (39) 14
Slide 15: Product for large veterinary laboratories in North America
Product for large veterinary laboratories in North America CellaVision® DM96 Vet • Analyzer for the veterinary market in the US and Canada. • An adapted version of the existing analyzer for human blood with the capacity for the most common companion animals. • Marketed to about 100 large veterinary
Slide 16: New product for collaborating laboratories
New product for collaborating laboratories CellaVision® Image Capture System • Complementary product for satellite laboratories in a health network. • A camera, computer and software enables laboratories to digitalize their manual blood analyses and via the network perform the analysis where there i
Slide 17: The market confirms added value
The market confirms added value Resolves skills shortage at our small sites “The Image Capture System could be placed in our smaller, remote regional laboratory sites where maintaining proficiency in blood film examination has been difficult”. Monika Hudoba, Centralization of our blood analysis Vanc
Slide 18: Shareholders
Shareholders Shareholders % Number of shareholders 1900 Stiftelsen Industrifonden 15,0 1731 1700 1635 Metallica Förvaltnings AB 11,6 1500 1444 Christer Fåhraeus incl. companies 10,1 Livförsäkrings AB Skandia 6,8 1300 Anders Althin 4,0 1100 SHB: Tredje AP‐fonden 3,4 878 900 763 Lannebo Fonder 3,4 675
Slide 19: Share performance 2009-2012
Share performance 2009‐2012 May 2, 2012: 18.10 SEK Jan 2, 2012: 13.25 SEK 2011: +27% 19 5/2/2012
Slide 20: Board and Management
Board and Management Ledning Styrelse Yvonne Mårtensson Johan Wennerholm Hans‐Inge Bengtsson Lars Gatenbeck Christer Fåhraeus Sven‐Åke Henningsson CEO CFO QA Manager Chairman Stefan Bengtsson Ron Hagner Peter Wilson Lars Henriksson Roger Johanson Anna Malm Bernsten COO VP Sales & Business Marketing
Slide 21: Learn more!
Learn more! • Web: www.cellavision.com • Blog: http://blog.cellavision.com • App: CellAtlas® • Introduce: www.introduce.se • Redeye: www.redeye.se 21 5/2/2012